Limosilactobacillus reuteri DSM 17938 and ATCC PTA 6475 for the treatment of moderate to severe irritable bowel syndrome in adults: a RCT

[Meleber]

Research:

Limosilactobacillus reuteri DSM 17938 and ATCC PTA 6475 for the treatment of moderate to severe irritable bowel syndrome in adults: a randomized controlled trial

Source: frontiersin.org/journals/ga...

Background:

Irritable bowel syndrome (IBS) is a common functional gastrointestinal disorder in adults. Systematic reviews with meta-analyses have demonstrated the efficacy and safety of probiotics in improving symptoms of IBS.

Aim:

The aim of the study was to demonstrate the efficacy and safety of Limosilactobacillus reuteri (L. reuteri) DSM 17938 combined with L. reuteri ATCC PTA 6475 regarding improving the symptoms associated with IBS in adults.

Methods:

A randomized, double-blind, placebo-controlled clinical trial was conducted in 140 adults aged 18 years to 65 years with a diagnosis of IBS (based on the Rome IV criteria). After 2 weeks of washout, subjects were randomized to receive either 2 × 108 colony-forming units (CFUs) of L. reuteri DSM 17938 combined with L. reuteri ATCC PTA 6475 plus standard of care or placebo plus standard of care for 14 weeks, followed by a post-intervention period of 2 additional weeks. Changes in gastrointestinal symptoms (as measured with the GSRS-IBS), stool pattern (as measured with the Bristol scale), quality of life, depression and anxiety, frequency of adverse events, and fecal calprotectin concentrations were evaluated.

Results:

In total, 70 subjects were allocated to receive L. reuteri and 70 were allocated to receive placebo. During the pre-randomization phase, no differences were observed between the groups in terms of IBS-associated symptoms and stool consistency. Starting at week 6 of the intervention, subjects in group L. reuteri showed a significant improvement in IBS-associated symptoms (p < 0.01). A significant improvement was also observed in fecal calprotectin concentration in the L. reuteri group at the end of interventions (30.2 ± 11.8 mg/g of stool in the L. reuteri group and 41.6 mg/g ± 10.7 mg/g in the placebo group; p = 0.019). The frequency of adverse events was similar between groups.

Conclusions:

A twice-a-day intervention for 14 weeks is safe and effective, reduces the symptoms associated with IBS in adults aged 18 years to 65 years, improves stool consistency, and reduces symptoms associated with anxiety after 6 weeks.

[Meleber]

As a 'last resort', this is the only probiotic combination I'm willing to try for alleviating my IBS C symptoms. The brand is hard to find in the Netherlands, don't think there's a distributor of BioGaia, but I managed to buy it online in the EU.

[bluejourney in reply to Meleber]

I made some of Dr William Davis’s L-Reuteri yogurt, featured in his book “Super Gut”. It definitely has an effect - I felt great for the first few weeks, though I’m not sure the L-Reuteri colonises in your gut - you need to keep taking it to get the effects.

[Meleber in reply to bluejourney]

As far as I know it won't persist in the gut after you stop taking them. Maybe the effect will last for a short period but then you have to take them again. But if it should help to alleviate my symptoms I'm willing to pay for it, as long as the monthly costs aren't too high for me. But I haven't taken any yet, I'm waiting for the delivery. The package should arrive in a few days.

[Meleber in reply to bluejourney]

Are you still taking these probiotic strains?

[bluejourney]

Not taking them atm. Just about to start a 30 course of Allimed for IMO. I’ve got my overgrowth pretty low using the AIR2 and diet, and a couple of courses of Rifaximin, so am hoping the antimicrobials should work ok now. I plan to make some more L-reuteri yoghurt when I’ve finished the IMO treatment, as it makes you feel great and is delicious.

[Meleber]

Review: "Limosilactobacillus reuteri in Health and Disease "

Abstract

"Limosilactobacillus reuteri is a microorganism with valuable probiotic qualities that has been widely employed in humans to promote health. It is a well-studied probiotic bacterium that exerts beneficial health effects due to several metabolic mechanisms that enhance the production of anti-inflammatory cytochines and modulate the gut microbiota by the production of antimicrobial molecules, including reuterin. This review provides an overview of the data that support the role of probiotic properties, and the antimicrobial and immunomodulatory effects of some L. reuteri strains in relation to their metabolite production profile on the amelioration of many diseases and disorders. Although the results discussed in this paper are strain dependent, they show that L. reuteri, by different mechanisms and various metabolites, may control body weight and obesity, improve insulin sensitivity and glucose homeostasis, increase gut integrity and immunomodulation, and attenuate hepatic disorders. Gut microbiota modulation by ingesting probiotic L. reuteri strains could be a promising preventative and therapeutic approach against many diseases and disorders."

Link to source: mdpi.com/2076-2607/10/3/522